Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 151 DLBCL atezolizumab consolidation in high-risk DLBCL
2022-501076-26-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by HOVON. Primary endpoint: Disease-free survival. Planned start Dec 2022; status: authorised.
02
Drugs
atezolizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2022-501076-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501076-26-00.